Respiratory Syncytial Virus Infection

Respiratory syncytial virus (RSV) is a highly contagious, seasonal negative-sense single-stranded RNA virus that causes respiratory tract infections affecting individuals of all ages. While it typically presents with mild, cold-like symptoms such as runny nose, cough, low-grade fever, and nasal congestion in healthy individuals, RSV can lead to severe lower respiratory tract illnesses—including bronchiolitis and pneumonia—especially in infants under 6 months, premature babies, older adults, and those with underlying medical conditions or weakened immune systems. Transmission occurs via direct contact with infected respiratory secretions, droplets from coughing or sneezing, or indirect contact with contaminated surfaces. Although no specific antiviral treatment is widely available, supportive care including hydration, oxygen therapy, and hospitalization in severe cases is standard. Monoclonal antibody prophylaxis is available for high-risk infants. RSV remains the leading cause of infant hospitalization in the U.S., underscoring the importance of preventive measures and early medical intervention in vulnerable populations.

References:

[1]. Respiratory Syncytial Virus Infectious Disease (RSV). malacards.

Respiratory Syncytial Virus Infection (18):

Targets:	RSV (14) DNA/RNA Synthesis (3) Influenza Virus (2) β-glucuronidase (1) Drug Metabolite (1) Dengue Virus (1) Drug Derivative (1) HSV (1)

Cat. No.	Product Name	CAS No.	Purity	Chemical Structure

HY-P99804

Clesrovimab	2429913-18-6	99.77%
Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody targeting the respiratory syncytial virus (RSV) protein F. Clesrovimab binds to pre-fusion and post-fusion forms of RSV-A fusion protein with high affinity, with corresponding K_D values of 71 pM and 480 pM, respectively. Clesrovimab is applicable for the research of RSV infection.

HY-P991492

RSM-01
RSM-01 is a monoclonal antibody targeting site Ø of the pre-fusion F glycoprotein (Fusion glycoprotein F0) of respiratory syncytial virus (RSV). RSM-01 can be used in studies related to RSV infection.

HY-P1837

Influenza HA (518-526)	186302-15-8	98.28%
Influenza HA (518-526) is an H-2d-restricted CTL epitope derived from influenza virus hemagglutinin. Influenza HA (518-526) is highly conserved across various H5N1, some H9N2, and H1N1 strains. Influenza HA (518-526) binds to the mouse MHC class I allele K^d to form a complex, which is then recognized by specific CD8⁺ T cells. Influenza HA (518-526) is an immunodominant epitope in influenza-infected BALB/c mice, and it stimulates CD8⁺ T cells to secrete IFN-γ to induce a robust immune response. Currently, Influenza HA (518-526) is widely used in research related to respiratory syncytial virus (RSV), influenza virus, and H5N1 influenza.

HY-12983B

ALS-8112-TP	1445383-14-1
ALS-8112-TP is the 5'-triphosphate metabolite of ALS-8112 (HY-12983). ALS-8112-TP is a potent, selective and competitive respiratory syncytial virus (RSV) RNA polymerase inhibitor, with selectivity against polymerases from host or viruses unrelated to RSV such as hepatitis C virus (HCV). ALS-8112-TP can be efficiently recognized by the recombinant RSV polymerase complex, causing chain termination of RNA synthesis. ALS-8112-TP can be used for RSV-infection research.

HY-173189B

2-5A TEA	72351-33-8
2-5A (2′,5′-ApApA; 2′,5′-trioligoadenylate; 5'-O-Triphosphoryladenylyl-(2'→5')-adenylyl-(2'→5')-adenosine) TEA is a 5'-triphosphorylated (2',5') oligoadenylate. 2-5A TEA is an immunotransmitter that fuels RNase L immunity. 2-5A TEA degrades viral mRNA and inhibits protein synthesis by binding to RNase L and activating its endoribonuclease activity. 2-5A TEA can be used in RSV and cancer research.

HY-P992423

NIAID RSVF2-5
NIAID RSVF2-5 is a human monoclonal antibody fragment. NIAID RSVF2-5 binds to conserved, distinct conformational epitopes on RSV fusion glycoprotein, and shows activity against RSV subgroup A and B strains. NIAID RSVF2-5 reduces pulmonary and lung viral titers in RSV-infected rodents. NIAID RSVF2-5 can be used for the research of respiratory syncytial virus infection.

HY-N17236

Forsyshiyanine A	2767053-65-4
Foryshiyanine A is a triterpenoid alkaloid. Foryshiyanine A possesses anti-inflammatory activity, inhibiting the release of β-glucuronidase from rat polymorphonuclear leukocytes. Foryshiyanine A exhibits antiviral activity, with an EC₅₀ of 4.5 μM against respiratory syncytial virus (RSV) and an IC₅₀ of 7.3 μM against influenza A virus (H1N1). Foryshiyanine A reduces viral load by disrupting viral replication and entry. Foryshiyanine A may be used for the researches of inflammation and infection.

HY-P992301

Anti-RSV F Antibody (R4.C6)
Anti-RSV F Antibody (R4.C6) is a monoclonal antibody against RSV F, with a K_d of 0.34 nM for the post-fusion RSV F trimer. Anti-RSV F Antibody (R4.C6) recognizes a unique neutralizing epitope spanning epitopes II and IV on both pre-fusion and post-fusion RSV F. Anti-RSV F Antibody (R4.C6) can be used in studies related to respiratory syncytial virus infection.

HY-P992175

ADI-14448
ADI-14448 is a RSV prefusion fusion glycoprotein inhibitor and HMPV fusion glycoprotein inhibitor, with a K_d of 3.8 × 10^-10 M for RSV preF. ADI-14448 binds to epitope III of RSV preF, thereby blocking viral infection. ADI-14448 neutralizes RSV subtype A and HMPV subtype A1. ADI-14448 can be used in studies related to respiratory syncytial virus infection and metapneumovirus infection.

HY-P992174

ADI-14359
ADI-14359 is an antibody that binds to RSV postF, with a K_D value of 387 nM, and exhibits non-neutralizing activity. ADI-14359 binds to antigenic site I on RSV postF through interactions of its conserved CDR H3 motif, germline-encoded IGKV1-39 light chain residues and heavy chain residues, where the light chain mediates preferential binding to postF by conflicting with the rearranged preF region. ADI-14359 can be used in studies related to respiratory syncytial virus (RSV) infection.

HY-183331

YXX0237	860445-85-8
YXX0237 is an orally active anti-hypoxic agent. YXX0237 upregulates mRNA expression of FGF21 and GDF15 via activation of the ISR/ATF4 transcriptional axis. YXX0237 exhibits low cytotoxicity. YXX0237 enhances hypoxic survival in mice. YXX0237 can be used for the research of acute mountain sickness and hypoxia-related diseases.

HY-N16801

Genkwanol B	142674-67-7
Genkwanol B is a natural flavonoid.

HY-W108474

Ethyl (S)-2-aminobutanoate (hydrochloride)	91462-82-7
Ethyl (S)-2-aminobutanoate hydrochloride (Ethyl (2S)-2-aminobutanoate hydrochloride) is an antiviral compound. Ethyl (S)-2-aminobutanoate hydrochloride exhibits antiviral activity against RSV A2. Ethyl (S)-2-aminobutanoate hydrochloride can be used in research related to respiratory syncytial virus and DENV-2.

HY-182030

RSV fusion protein IN-1
RSV fusion protein IN-1 is an orally active RSV pre-fusion F protein inhibitor with an IC₅₀ of 0.10 nM against RSV. RSV fusion protein IN-1 forms stable hydrogen bonds and π-π stacking interactions with pre-fusion F protein to block viral fusion and entry. RSV fusion protein IN-1 suppresses RSV F protein expression in epithelial cells. RSV fusion protein IN-1 reduces viral burden in the lungs of RSV-infected murine models.RSV fusion protein IN-1 can be used for the research of respiratory syncytial virus (RSV) infection.

HY-185215

GS-646089	1770840-57-7
GS-646089 is a broad-spectrum antiviral nucleoside analog that exhibits significant inhibitory activity against respiratory syncytial virus (RSV), human metapneumovirus (hMPV), rhinovirus (enterovirus) and enteroviruses. The IC₅₀ of GS-646089 targeting RNA-dependent RNA polymerase (RdRp) ranges from 43 to 46 nM. GS-646089 blocks viral replication by being converted into a triphosphate metabolite intracellularly, which competes with ATP for incorporation into nascent RNA strands and acts as an immediate chain terminator. GS-646089 is the parent compound of the double prodrug GS-7682 (HY-161877), and is used in studies of acute respiratory viral infections and infections caused by related pathogens.

HY-181025

JNJ-6231
JNJ-6231 is a long-acting RSV inhibitor.

HY-120660

AZD4316	1243324-08-4
AZD-4316 is a respiratory syncytial virus (RSV) L protein inhibitor. AZD-4316 has an inhibitory effect on RSV A subtypes (such as strain A2) and can effectively block viral replication in the early stage of infection (the viral entry stage). AZD-4316 is inactive when administered 12-24 hours after infection. AZD-4316 can be used for the research of RSV infection.

HY-108002

A 33903	70890-53-8
A 33903 is a respiratory syncytial virus (RSV) replication inhibitor. A 33903 can be used for the research of RSV-infection.

Name
Email *

	Sorry, but the email address you supplied was invalid.